Bortezomib: a new therapeutic option for POEMS syndrome.

Clicks: 373
ID: 79816
2010
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Star

Ranked #1 of 9 articles by views in European journal of haematology

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
POEMS syndrome with its classical five findings (Polyneuropathy, Organomegaly, Endocrinopathy, M protein, and Skin changes) is a rare multisystem disease. Proinflammatory and proangiogenic cytokines play important roles in its pathogenesis. Treatment options are still debated.We present a 65-year-old man with POEMS syndrome who was successfully treated with bortezomib.After seven cycles of this protocol, serum M protein level declined to normal range, and near-to-complete remission was achieved. His symptoms of polyneuropathy improved dramatically.Bortezomib may be an effective and safe therapeutic option for patients with POEMS syndrome.
Reference Key
kaygusuz2010bortezomibeuropean Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Kaygusuz, Isik;Tezcan, Hakan;Cetiner, Mustafa;Kocakaya, Ozan;Uzay, Ant;Bayik, Mahmut;
Journal European journal of haematology
Year 2010
DOI
10.1111/j.1600-0609.2009.01341.x
URL
Keywords
mediterranean region forest management geographic information systems deadwood reference values physiographic parameters

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.